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Introduction
Long-lived memory B cells and specific antibodies have been reported to persist in the body for decades after specific vaccination. [1] [2] [3] One of the central questions concerning this phenomenon concerns the maintenance of this memory in the absence of repeated stimulations with the original vaccine. Experiments in mice suggested that the survival of memory B cells depended neither on constant cell proliferation nor on the presence of the immunizing antigen. 4, 5 It was therefore assumed that these cells remain quiescent for long periods of time, but nonetheless react very rapidly if they encounter the immunizing antigen. It has also been suggested that the presence of specific serum antibodies is directly linked to the presence of the corresponding memory B cells. In this model, each new antigenic stimulation provides bystander T cell help for the previously generated memory B cells, leading to the differentiation of some of these cells into Ig-secreting plasmocytes. 6 An alternative explanation for the continued presence of serum antibodies a long time after the initial pathogen encounter has also been put forward, according to which each vaccination induces both the immediate differentiation of plasmocytes and the formation of long-lived plasma cells. 7, 8 These memory plasma cells would survive in bone marrow and would be replaced, at a certain rate, by plasmablasts generated in response to new pathogens. 9 Smallpox vaccination is considered an ideal model for studies of the basis of long-term cellular and humoral memory. 10 Vaccinia virus was successfully used to eradicate variola virus, the etiologic agent of smallpox. As smallpox vaccination was stopped in the mid 1970s and smallpox was eradicated worldwide in 1977, 11 we can assume that people have not been re-exposed to the pathogen since then. Using ELISPOT assays following in vitro cell stimulation, we studied the maintenance of the vaccinia virus-specific memory B cell pool in the blood and spleen of normal individuals, and in those of patients who had -4 -undergone B cell-targeted immune interventions. We show here that long-lived memory B cells have their own central reservoir, the spleen, and seem to display their own homeostatic regulation, independent of the presence of the corresponding plasmocytes.
Materials and Methods

Viruses
The modified vaccinia virus Ankara (MVA), which was used as the antigen in the B-cell ELISPOT assay, was amplified in chicken embryo fibroblasts and purified by centrifugation on a sucrose cushion. Alternatively, highly purified MVA preparations for use in ELISA were produced by centrifugation on two successive sucrose gradient cushions. Titers were determined by plaque assays on confluent chicken embryo fibroblast monolayers grown in six-well tissue culture plates. 12
Patients and controls
Approval for this research was granted by the "Comité de protection des personnes Ile-de-France II". Written informed consent was obtained from all patients. The characteristics of the subjects, including age, sex, diagnosis and medication taken at the time of sample collection are detailed in Supplemental Tables S1-S3 Supplemental Tables S1-S3 . As a control, we obtained blood samples from 16 healthy subjects from the blood bank (Etablissement 
Isolation of cells and serum
Spleen samples were recovered in complete medium (RPMI-1640, 100 mU/ml penicillin, 100 µg/ml streptomycin (all from Invitrogen) and 10% fetal calf serum (FCS, HyClone, Logan, UT) after surgery and were stored at 4°C until processing. In some cases, the entire spleen was maintained under physiological perfusion for 6 h before cell isolation, as described by Buffet et al., 13 with no influence in results. Cell suspensions were obtained by mechanical dissociation in complete medium. Peripheral blood and bone marrow aspirates were collected in heparin or EDTA tubes for cell isolation. In all experiments, mononuclear cells (MNC) from blood, bone marrow aspirates or spleen cell suspensions were isolated by centrifugation on a Ficoll-Hypaque density gradient. Red blood cells were lysed and the remaining cells were washed with 2% FCS in PBS and resuspended in complete medium containing 50 µM β-mercaptoethanol. Cell viability after isolation was determined by counting with Trypan Blue exclusion and only samples with viability exceeding 90% were considered. In the case of patient RTX6 (B cell content below 1%), the splenic preparation was enriched for B cells, using the B cell-negative isolation kit (Dynal-Biotech, Oslo, -6 -Norway) according to the manufacturer's recommendations. Such enrichment was performed in order to obtain a measurable value in ELISPOT assay. Serum was prepared by clotting blood collected in SST tubes (BD Diagnosis, Franklin Lakes, NJ) or by treating one volume of plasma with one volume of BC thrombin reagent (Dade Behring, Marburg, Germany) for 10 min at room temperature. Serum was then inactivated by heating for 30 min at 56°C and frozen in aliquots.
Flow cytometry
Cells were routinely labelled with the following antibodies: fluorescein isothiocyanate 
Memory B cell assay
This procedure was adapted from that described by Crotty et al. 14 
Statistical Methods
Non parametric Kruskal-Wallis two-sided score test was used to compare the frequency of vaccinia virus-specific memory B cells between blood and spleen and between controls and splenectomized patients, as well as serum titers of vaccinia virus antibody between the different groups studied. For the 23 vaccinated individuals for whom both parameters were known, we estimated the Spearman coefficient of correlation R 2 between anti-vaccinia virus antibody titers and the frequency of vaccinia virus-specific memory B cells. All analyses were performed using SAS Software 9.1 (SAS Institute, Cary, NC).
Results
Anti-vaccinia virus memory B cells are concentrated in the spleen
We first compared the proportion of memory B cells against vaccinia virus in the blood and spleen several decades after vaccination, in samples obtained from vaccinated (Table 1 , V1-V20) or non-vaccinated (Table 1 , C1-C9) individuals. The modified vaccinia virus Ankara (MVA) is a replication-deficient strain of vaccinia virus that was tested as a safer vaccine for smallpox vaccination. 16 It was used throughout this study for the ELISPOT and ELISA assays, to assess cellular and serological anti-smallpox/vaccinia virus memory. Blood or splenic mononuclear cells were analyzed by ELISPOT against MVA, after 6 days of in vitro polyclonal stimulation, as described by Crotty et al. 14 We determined the proportion of anti-vaccinia virus-specific B cells as the ratio of anti-MVA IgG + cells to total IgG + cells ( Figure 1A) . The members of the vaccinated cohort were aged between 31 and 75 years, whereas the non-vaccinated controls were all under the age of 28 years (Table 1 ). We first confirmed previous results, 1 showing that a median of 0.07% of circulating IgG + memory B cells were specific for vaccinia virus in the blood of individuals vaccinated more than 30 years previously, with the values observed lying between 0.01 and 0.16% ( Figure 1B ; Table   1 ). The absence of anti-vaccinia virus memory B cells in the non-vaccinated controls indicated an absence of cross-reactive responses induced by closely related viruses. We retrieved splenic fragments, mostly from patients who had undergone surgery for a pancreatic tumor (see description of patients in Supplemental Table S1 ). Splenic mononuclear cells from nine patients vaccinated at least 30 years ago, and from two nonvaccinated controls (7 and 17 years old) were analyzed with the anti-MVA ELISPOT assay.
The proportion of anti-vaccinia virus memory B cells in the spleen was much higher, at 0.24%, with values ranging from 0.07 to 0.62% ( Figure 1B ; V10-V18 in Table 1 ). No -10 -vaccinia virus-specific IgG secreting cells were detected in control culture with unstimulated cells either from blood or from spleen. In three patients from whom both splenic and blood samples could be obtained, the proportion of memory B cells in the spleen and blood differed by a factor of three to ten ( Figure 1B insert; V10, V13, V18, in Table 1 ), these differences being observed even in cases in which the frequency of splenic memory B cell was in the lower range ( Table 1 , V13 and V18).
Variable impact of rituximab-induced B cell depletion on anti-vaccinia virus memory B cell survival
It has been reported that the circulation is depleted of most of its B cells following treatment with rituximab, a B cell-depleting anti-CD20 antibody. However, the extent of this depletion seems to be more variable in lymphoid organs. [17] [18] [19] B cell recovery in the blood starts about six months after the end of the treatment, with normal levels reached after 12 to 20 months. We analyzed the blood of five patients treated with rituximab 25 to 39 months previously (Table 2; Figure 1C ). No circulating anti-vaccinia virus memory B cells were detected in two patients (RTX3: <0.007%, RTX5: <0.04%), whereas such cells were detected in two others (RTX4, RTX1), albeit at a low frequency (0.01 and 0.04%).
Surprisingly, in the last patient (RTX2), memory B cells specific for vaccinia virus were found 26 months after rituximab treatment (RIT; 2 cycles, see description of patients in Supplemental Tables S2) at a frequency much higher (0.32%) than that observed in the blood of normal individuals analyzed several decades after vaccination. An increase in serum B-cell-activating factor (BAFF) concentration has been reported after RIT in some patients. 20 Serum BAFF level was normal in patient RTX2 (not shown), leaving us with no -11 -clear explanation for these findings. Thus, most patients treated with rituximab displayed a lower frequency of anti-vaccinia virus memory B cells in their blood.
Some splenic anti-vaccinia virus memory B cells can resist rituximab treatment
Given the highly variable pattern of memory B cell recovery after RIT, and assuming that the spleen could act as a major reservoir for these cells, we decided to determine the frequency of residual memory B cells in the spleen after RIT. We focused on three cases of idiopathic thrombocytopenic purpura (ITP) who underwent splenectomy after a failure to respond to treatment. One patient (RTX6, Table 2 ) was splenectomized three months after RIT. No B cells were detected in his blood and the percentage of B cells in the spleen was very low (around 0.1%). These cells were found to be almost exclusively IgG + CD27 + (Figure 2) , thus suggesting a memory phenotype. After in vitro stimulation, anti-vaccinia virus memory B cells were detected, amounting to 0.14% of total IgG + B cells ( Table 2 ).
The second patient (RTX7, Table 2 ) underwent splenectomy six months after the end of RIT. B cells were beginning to reappear in his blood (1.6%, versus 10% in controls) and spleen (10% versus 40% in controls). Memory B cells against vaccinia virus were not detectable in his blood and amounted to 0.06% in his spleen. In the third patient (RTX8, Table 2 ) in which the spleen was retrieved 15 months after the end of RIT, B cells recovered to normal values in blood and spleen ( Supplemental Table S2 ) but vaccinia virus-specific memory B cells could only be found in the spleen at a frequency of 0.06% of total IgG secreting cells. These three cases evoke that a small pool of splenic anti-vaccinia virus memory B cells (a few tens of thousands memory B cells) have resisted to RIT along with other IgG + switched B cells. As the spleen replenishes with newly formed IgG + B cells, this pool may tend to dilute itself.
-12 -
Splenectomy affects the circulating long-lived memory B cell pool
If long-lived memory B cells are principally maintained in the spleen, then the frequency of these cells should be significantly lower in patients that have been splenectomized several years ago. We collected blood samples from five patients, who had undergone splenectomy 7 to 50 years previously (see description of patients in supplemental Table S3 ). The levels of circulating anti-vaccinia virus memory B cells were all below the median of the control values ( Figure 1C ; Table 2 , SPL4: no detectable anti-vaccinia virus memory B cells, SPL1: 0.01%, SPL3: 0.009%, SPL2, for which small accessory spleens were detected: 0.04% and SPL5: 0.06%). These results suggest that splenectomy may lead to a consistent loss of long-lived memory B cells and that this deficiency can persist even several decades after the surgical procedure. Nevertheless, these cells can still be found, albeit at diminished levels, in the blood of most of these patients, suggesting the existence of other minor storage sites outside the spleen.
Further evidence to support this hypothesis is provided by the case of a rituximab-treated patient who underwent splenectomy two months after four cycles of RIT and who was analyzed 36 months after splenectomy. A small proportion of circulating anti-vaccinia virus memory B cells could be detected in this patient (RTX9: 0.02%, Table 2 ).
In two cases in which it was possible to analyze a bone marrow sample not contaminated with malignant cells or blood, we detected no significant enrichment of anti-vaccinia virus memory B cells over average values for blood (V19: 0.04%, V20: 0.02%, Table 1 ).
-13 -
No significative correlation between vaccinia virus-specific serum antibody titers and blood memory B cells
We estimated the correlation between the proportion of memory B cells and the level of specific antibodies against vaccinia virus, by using ELISA to determine serum anti-vaccinia virus antibody titers in the blood of most of the subjects analyzed in this study (Tables 1 and 2). A large proportion of the patients vaccinated more than 30 years ago had measurable levels of anti-vaccinia virus antibodies, consistent with the findings of previous reports. [1] [2] [3] We took a value of 0.075, the median value for non-vaccinated individuals, as the threshold below which levels of IgG against vaccinia virus were considered negative (Table 1 and Supplemental Figure S1 ). Three patients with no anti-vaccinia virus antibodies were found to have vaccinia virus-specific memory B cells in their blood (V6, Table 1 and RTX4, SPL5, Table 2 ). Conversely, in three patients with a reasonably high level of antivaccinia virus antibodies, no circulating anti-vaccinia virus memory B cells could be detected in their blood (V13, Table 1 and SPL4, RTX3, Table 2 ). No significative correlation was found in this study between the proportion of memory B cells and the titer of antibodies specific for vaccinia virus (Figure 3 , for n=23 individuals, R 2 =-0.03, p-value=0.88).
Discussion
We studied the persistence of vaccinia virus-specific memory B cells in the blood and spleen of normal individuals and of patients who had undergone B cell-targeted immune interventions, splenectomy or anti-CD20 mediated B cell depletion.
In individuals vaccinated with the vaccinia virus during their childhood (i.e., more than 30 years before this study) about 0.24% of splenic IgG + B cells recognize this pathogen. This -14 -proportion is significantly higher than that for the blood (about 0.07%, consistent with previous reports 1, 3 ). Taking into account the size of the blood and splenic B cell compartments (approximately 5x10 8 and 4x10 10 B cells respectively, with 10 to 20% IgG + B cells), there are, on average, around 0.5 to 1 x 10 5 memory B cells against vaccinia virus circulating in the blood of vaccinated individuals, and 1 to 2 x 10 7 such cells in the spleen.
Assuming that all pathogens display similar numbers of immunodominant B cell epitopes, thereby engaging similar numbers of memory B cells, this suggests that the splenic B cell compartment has an overall memory against 10 2 to 10 3 different pathogens. The values proposed for the repertoire of long-lived plasma cells in humans are of the same order of magnitude. 21 It has been suggested that some long-lived plasma cells may be regularly replaced by newly formed plasmablasts, although it remains unclear how this replacement takes place. 9 A similar turnover may occur for memory B cells, but again, we know little of the basic mechanism of memory formation and the signals conferring on these cells a shorter or longer existence within the individual.
We could not study lymph nodes or Peyer's patches from vaccinated individuals, raising questions about the possibility of other secondary lymphoid organs constituting an additional reservoir for long-lived memory B cells. There was a severe reduction, although not a complete loss, of circulating anti-vaccinia virus memory B cells in most splenectomized patients. This suggests that these cells survive as such in the blood or that there are other accessory niches outside the spleen. Rituximab, a chimeric human/mouse anti-CD20 antibody, has become a major treatment for B cell-related lymphomas and autoimmune disorders. Two to four years after RIT, most patients presented much lower levels of circulating anti-vaccinia virus memory B cells. Analysis of the spleen a few months after RIT showed the presence of residual B cells, with the IgG + phenotype only, -15 -including a small proportion of long-lived memory B cells, despite the total absence of circulating B cells. Strikingly, a low level of circulating anti-vaccinia virus memory B cells was also observed in one patient, three years after a splenectomy performed 2 months after the completion of rituximab treatment. Since B cell depletion was still complete in the blood at the time of splenectomy, this unique case strengthens the view that there are other storage sites for memory B cells, but that these sites do not seem to compensate quantitatively for the absence of the spleen. Bone marrow has been identified as a preferential niche for long-lived plasma cells and for some memory T and B cells. 7, 8, 22, 23 We did not detect any specific enrichment of vaccinia virus memory B cells in the two bone marrow samples that we have analyzed. Overall, these results suggest that the spleen is a major niche for long-lived memory B cells but that despite drastic B cell depleting treatment such as RIT or splenectomy, these cells can slowly reappear in the blood. These treatments therefore do not seem to result in the systematic eradication of the B cell memory carried by these patients, notably the one related to childhood vaccinations.
Consistent with this interpretation, the response to recall antigens seemed to be strongly decreased by rituximab treatment in one study of lymphoma patients, 24 whereas this response was found to be preserved in another study. 25 The concept of two layers of long-term humoral memory sustained by the existence of long-lived memory B cells and long-lived plasma cells emerged some years ago 7, 8 and has subsequently been strongly supported by experimental data. 26 It has also been proposed that the maintenance of antibodies several decades after a vaccination or an infection was due to a constant production by non specific stimulation of memory B cells. 6 In the later case, there should be a quantitative correlation between the frequency of memory B cells and the level of serum antibodies. In several reports in which these parameters were analyzed after -16 -vaccination or natural infections, the strength of the correlation varied considerably, 1, 3, [27] [28] [29] suggesting that bystander stimulation of memory B cells into short lived plasma cells was unlikely to be a general mechanism. In the present study, in which it was possible to analyze more strongly contrasting situations, no correlation was observed for the 23 patients for whom both serum titers of anti-vaccinia virus antibodies and memory B cells could be determined. In fact, a complete dissociation was observed in several cases, with anti-vaccinia virus antibodies detected in the total absence of the corresponding memory B cells, or memory B cells being present in the absence of the corresponding antibodies. This observation gives additional support to the proposal that long-lived memory B cells and long-lived plasma cells in humans are independent entities, with long-lived plasma cells able to survive for several decades independently of the presence of memory B cells of the same specificity. 3, 8, 30 Nevertheless, B cell memory does not seem to be a uniform phenomenon and one can not exclude that some antigen-specific or non specific stimulation of long-lived memory B cell could also contribute to the production of antibodies. 6, 31 Many unanswered questions remain concerning the homeostatic regulation of long-lived memory B cells. If the spleen is indeed, as proposed here, a main reservoir for these cells, then most memory B cells may only react to a specific recall pathogen once it reaches the spleen, whereas the circulating memory B cells and neutralizing antibodies will provide a first line of defense at the beginning of infection. Supplemental Tables S2-S3. -22 - 
